Sign in
Taking peoplePhase 4

Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis

Key facts

Who runs it
Scandinavian Critical Care Trials Group
Where
Denmark and Sweden22 sites in 2 countriesChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 4
People taking part
5,800 people, planned
Started
26 Jun 2025
Expected to end
30 Mar 2029
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Meropenem
  • Piperacillin/Tazobactam
Record updated
3 July 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Age ≥ 18 years
  • Sepsis (including septic shock) defined according to the Sepsis-3 criteria (1), i.e., suspected or documented infection and an acute increase of ≥ 2 points in the Sequential Organ Failure Assessment (SOFA) score (a marker of acute organ dysfunction)
  • Critical illness defined as use of at least one of the following:; Invasive mechanical ventilation; Non-invasive ventilation; Continuous use of continuous positive airway pressure (CPAP) for hypoxia; Oxygen supplementation with an oxygen flow of ≥ 10 litres (L)/minute independent of delivery system and total flows; Continuous infusion of any vasopressor or inotrope (excluding strictly procedure-related infusions)
  • Clinical indication for empirical treatment with either meropenem or piperacillin/tazobactam

Who cannot take part

  • Preceding intravenous treatment with meropenem or piperacillin/tazobactam for \> 24 hours prior to screening
  • Known infection/colonialization with microorganism with acquired resistance against meropenem or piperacillin/tazobactam within the previous 3 months (e.g., ESBL-, AmpC- or carbapenemase-producing bacteria)
  • Previously randomised into the EMPRESS trial
  • Known hypersensitivity or allergy to beta-lactam antibiotics
  • Suspected or documented central nervous system infection
  • Fertile women \< 60 years of age with known pregnancy or positive urine human gonadotropin (hCG) or plasma hCG
  • Current or planned use of valproate within 30 days from randomisation
  • Patient included in another interventional trial where co-enrolment with EMPRESS is not permitted
  • Informed consent following inclusion expected to be unobtainable
  • Patient under coercive measures

This trial has no sites in United States.

It has sites in 2 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

The EMPRESS trial aims to test the two most commonly used antibiotics (meropenem and piperacillin/tazobactam) among intensive care patients with sepsis (blood poisoning), as the safety of these two drugs is unclear in this group of patients.

The 2 groups in the trial

  • MeropenemTreatment being tested

    Participants in the experimental intervention arm will receive 1 g of IV meropenem three times daily administered according to usual clinical practice (i.e., intermittent-, prolonged-, or continuous infusion) until discharge from the participating site, death, or termination of empirical antibiotic therapy (including initiation of definitive treatment).

  • Piperacillin/TazobactamExisting treatment, for comparison

    Participants in the control arm will receive 4/0.5 g of intravenous piperacillin/tazobactam four times daily administered according to usual clinical practice (i.e., intermittent-, prolonged-, or continuous infusion) until discharge from the participating site, death, or termination of empirical antibiotic therapy (including initiation of definitive treatment).

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis (EMPRESS) Trial
Publications
Record updated
3 July 2025